Evaluation of recent patent applications for the diagnosis and treatment of autism and pervasive developmental disorders

Bibliography

• Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Associate, Washington DC, USA (1994).
   Google Scholar
• International Classification of Diseases, 10th Edition. World Health Organization 1992, Geneva, Switzerland.
   Google Scholar
• PALMEN SJ, VAN ENGELAND H, HOF PR, SCHMITZ C: Neuropathological findings in autism. Brain (2004) 127(pt.12):2572-2583.
   PubMed Web of Science ®Google Scholar
• LAM KS, AMAN MG, ARNOLD LE: Neurochemical correlates of autistic disorder: a review of the literature. Res. Dev. Disabil. (2005) in press.
   PubMedGoogle Scholar
• ANDERSON GM HOSHINO Y: Neurochemical studies in autism. In: Handbook of Autism and Pervasive Developmental Disorders, Volume 1. Volkmar FR, Paul R, Klin A, Cohen D (Eds), John Wiley & Sons, Inc. (2005):453-472.
   Google Scholar
• SCHAIN RJ, FREEDMAN DX: Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatrics (1961) 58:315-320.
   PubMed Web of Science ®Google Scholar
• GORDON CT, STATE RC, NELSON JE, HAMBURGER SD, RAPOPORT JL: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch. Gen. Psychiatry (1993) 31(6):739-745.
   Google Scholar
• HOLLANDER E, PHILIPS A, CHAPLIN W et al.: A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology (2005) 30(3):582-589.
   PubMed Web of Science ®Google Scholar
• POSEY DI, LITWILLER M, KOBURN A, MCDOUGLE CJ: Paroxetine in autism. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(2):111-112.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, BRODKIN ES, NAYLOR ST, CARLSON DC, COHEN DJ, PRICE LH: Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J. Clin. Psychopharmacol. (1998) 18(1):62-66.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, NAYLOR ST, COHEN DJ, VOLKMAR FR, HENINGER GR, PRICE LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen. Psychiatry (1996) 53(11):1001-1008.
   PubMed Web of Science ®Google Scholar
• NAMEROW LB, THOMAS P, BOSTIC JQ, PRINCE J, MONUTEAUX MC: Use of citalopram in pervasive developmental disorders. J. Dev. Behav. Pediatr. (2003) 24(2):104-180.
   PubMed Web of Science ®Google Scholar
• RES. UNIT ON PEDIATRIC PSYCHOPHARMACOLOGY AUTISM NETWORK (RUPP): Resperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry (2005) 162(7):1361-1369
   PubMed Web of Science ®Google Scholar
• MALONE RP, CATER J, SHEIKH RM, CHOUDHURY MS, DELANEY MA: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J. Am. Acad. Adolesc. Psychiatry (2001) 40(8):887-894.
   PubMed Web of Science ®Google Scholar
• SHEA S, TURGAY A, CARROLL A et al.: Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics (2004) 114(5):634-641.
   PubMed Web of Science ®Google Scholar
• POSEY DJ, MCDOUGLE CJ: Pharmacotherapeutic management of autism. Expert Opin. Pharmacother. (2001) 2(4):587-600.
   PubMedGoogle Scholar
• STIGLER KA, POSEY DJ, MCDOUGLE CJ: Recent advances in the pharmacotherapy of autism. Expert Rev. Neurotherap. (2002) 2(4):499-510.
   PubMedGoogle Scholar
• MASI G: Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs (2004) 18(14):1031-1052.
   PubMedGoogle Scholar
• AMIR RE, VAN DEN VEYVER IB, WAN M et al.: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. (1999) 23(2):185-188.
   PubMed Web of Science ®Google Scholar
• CHESS S, FERNANDEZ P, KORN S: Behavioral consequences of congenital rubella. J. Pediatrics (1978) 93(4):669-703.
   Google Scholar
• AHLFORS K, IVARSSON SA, HARRIS S et al.: Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Scandinavian J. Infect. Dis. (1984) 16(2):129-137.
   PubMed Web of Science ®Google Scholar
• ZIMMER C: Do chronic diseases have and infectious root? Science (2001) 293(5537):1974-1977.
   PubMedGoogle Scholar
• GRIEM P, WULFERINK M, SACHS B, GONZALEZ J, GLEICHMANN E: Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol. Today (1998) 19(3):133-142.
   PubMedGoogle Scholar
• EDELSON SB, CANTOR DS: Autism: xenobiotic influences. Toxicol. Ind. Health (1998) 14(6):799-811.
   PubMedGoogle Scholar
• EDELSON SB, CANTOR DS: The neurotoxic etiology of the autistic spectrum disorders: a replication study. Toxicol. Ind. Health (2000) 16(6):239-247.
   Web of Science ®Google Scholar
• PANKSEPP J: A neurochemical theory of autism. Trends Neurosci. (1979) 2:174-177.
   Web of Science ®Google Scholar
• HORVATH K, STEFANATOS G, SOKOLSKI KN, WACHTEL R, NABORS L, TILDON JT: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Phys. (1998) 9(1):9-15.
   PubMedGoogle Scholar
• SANTANGELO SL, TSATSANIS K: What is known about autism: Genes, brain and behavior. Am. J. Pharmacogenomics (2005) 5(2):71-92.
   PubMedGoogle Scholar
• CICCODICOLA A, D’ESPOSITO M, ESPOSITO T et al.: Differentially regulated and evolved genes in the fully sequenced Xq/Yq pseudoautosomal region. Hum. Mol. Genet. (2000) 9(3):395-401.
   PubMedGoogle Scholar
• MARGOLIS RL, MCINNIS MG, ROSENBLATT A, ROSS CA: Trinucleotide repeat expansion and neuropsychiatric disease. Arch. Gen. Psychiatry (1999) 56(11):1019-1031.
   PubMedGoogle Scholar
• KLEIDERLEIN JJ, NISSON PE, JESSEE J et al.: CCG repeats in cDNAs from human brain. Hum. Genet. (1998) 103(6):666-673.
   PubMed Web of Science ®Google Scholar
• ICHTCHENKO K, HATA Y, NGUYEN T et al.: Neuroligin 1: a splice site-specific ligand for (β-neurexins. Cell (1995) 81(3):435-443.
   PubMed Web of Science ®Google Scholar
• ICHTCHENKO K, NGUYEN T, SÜDHOF TC: Structures, alternative splicing, and neurexin binding of multiple neuroligins. J. Biol. Chem. (1996) 271(5):2676-2682.
   PubMed Web of Science ®Google Scholar
• SCHEIFFELE P, FAN J, CHOIH J, FETTER R, SERAFINI T: Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. Cell (2000) 101(6):657-669.
   PubMed Web of Science ®Google Scholar
• CHIH B, ENGELMAN H, SCHEIFFELE P: Control of excitatory and inhbitory synapse formation by neuroligins. Science (2005) 307(5713):1324-1328.
   PubMed Web of Science ®Google Scholar
• CHUBYKIN AA, LIUX, COMOLETTI D, TSIGELNY I, TAYLOR P, SÜDHOF TC: Dissection of synapse induction by neuroligins. J. Biol. Chem. (2005) 280(23):22365-22374.
   PubMed Web of Science ®Google Scholar
• JAMAIN S, QUACH H, BETANCUR C et al.: Mutations of the X-linked genes encoding neurologins NLGN3 and NLGN4 are associated with autism. Nat. Genet. (2003) 34(1):27-29.
   PubMed Web of Science ®Google Scholar
• THOMAS NS, SHARP AJ, BROWNE CE, SKUSE D, HARDIE C, DENNIS NR: Xp deletions associated with autism in three females. Hum. Genet. (1999) 104(1):43-48.
   PubMed Web of Science ®Google Scholar
• LAUMONNIER F, BONNET-BRILHAULT F, GOMOT M et al.: X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am. J. Hum. Genet. (2004) 74(3):552-557.
   PubMed Web of Science ®Google Scholar
• SANE DC, BAKER MS: Human platelets possess tyrosylprotein sulfotransferase (TPST) activity. Thromb. Haemost. (1993) 69(3):272-275.
   PubMedGoogle Scholar
• CHEN NH, REITH ME, QUICK MW: Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. (2004) 447(5):519-531.
   PubMedGoogle Scholar
• ASHLEY-KOCH A, WOLPERT CM, MENOLD MM et al.: Genetic studies of autistic disorder and chromosome 7. Genomics (1999) 16(3):227-236.
   Google Scholar
• HIDALGO A: Growth and patterning from the engrailed interface. Int. J. Dev. Biol. (1998) 42(3):317-324.
   PubMedGoogle Scholar
• WURST W, BALLY-CUIF L: Neural plate patterning: upstream and downstream of the isthmic organizer. Nat. Rev. Neurosci. (2001) 2(2):99-108.
   PubMed Web of Science ®Google Scholar
• CONDRON BG, PATEL NH, ZINN K: Engrailed controls glial/neuronal cell fate decisions at the middle central nervous system. Neuron (1994) 13(3):541-554.
   PubMedGoogle Scholar
• HARZSCH S, MILLER J, BENTON J, DAWIRS RR, BELTZ B: Neurogenesis in the thoracic neuromeres of two crustaceans with different metamorphic development. J. Exp. Biol. (1998) 201(pt.17):2465-2479.
   PubMedGoogle Scholar
• MARIE B, BACON JP, BLAGBURN JM: Double-stranded RNA interference shows that engrailed controls the synaptic specificity of identified sensory neurons. Curr. Biol. (2000) 10(5):289-292.
   PubMed Web of Science ®Google Scholar
• SAUERESSIG H, BURRILL J, GOULDING M: Engrailed-1 and netrin-1 regulate axon pathfinding by association interneurons that project to motor neurons. Development (1999) 126(19):4201-4212.
   PubMedGoogle Scholar
• SIMON HH, THURET S, ALBERI L: Midbrain dopaminergic neurons: control of their cell fate by the engrailed transcription factors. Cell Tissue Res. (2004) 318(1):53-61.
   PubMedGoogle Scholar
• WANG X, HERBERG FW, LAUE MM et al.: Neurobeachin: a protein kinase A-activating, beige/Chediak-Higashi protein homologue implicated in neuronal membrane traffic. J. Neurosci. (2000) 20(23):8551-8565.
   PubMedGoogle Scholar
• SU Y, BALICE-GORDON RJ, HESS DM et al.: Neurobeachin is essential for neuromuscular synaptic transmission. J. Neurosci (2004) 24(14):3627-3636.
   PubMed Web of Science ®Google Scholar
• CASTERMANS D, WILQUET V, PARTHOENS E et al.: The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism. J. Med. Genet. (2003) 40(5):352-356.
   PubMed Web of Science ®Google Scholar
• JAHNG JW, WESSSEL TC, HOUPT TA, SON JH, JOH TH: Alternate promoters in the rat aromatic L-amino acid decarboxylase gene for neuronal and non-neuronal expression: an in situ hybridization study. J. Neurochem. (1996) 66(1):14-20.
   PubMedGoogle Scholar
• SUMI-ICHINOSE C, HASEGAWA S, ICHINOSE H et al.: Analysis of the alternative promoters that regulate tissue-specific expression of human aromatic L-amino acid decarboxylase. J. Neurochem. (1995) 64(2):514-524.
   PubMedGoogle Scholar
• RAMOZ N, REICHERT JG, SMITH CJ et al.: Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am. J. Psychiatry (2004) 161(4):662-669.
   PubMedGoogle Scholar
• PALMIERI L, PARDO B, LASORSA FM et al.: Citrin and aralar1 are Ca2+-stimulated aspartate/glutamate transporters in mitochondria. EMBO J. (2001) 20(18):5060-5069.
   PubMedGoogle Scholar
• GILBERG C, TRYGSTAD O, FOSS I: Childhood psychosis and urinary excretion of peptides and protein-associated peptide complexes. J. Autism Dev. Disord. (1982) 12(3):229-241.
   PubMedGoogle Scholar
• ISRANGKUN PP, NEWMAN HA, PATEL ST, DURUIBE VA, ABOU-ISSA H: Potential biochemical markers for infantile autism. Neurochem. Pathol. (1986) 5(1):51-70.
   PubMedGoogle Scholar
• REICHELT KL, HOLE K, HAMBERGER A et al.: Biologically active peptide-containing fractions in schizophrenia and childhood autism. Adv. Biochem. Psychopharmacol. (1981) 28:627-643.
   PubMedGoogle Scholar
• CHANG KJ, SU YF, BRENT DA, CHANG JK: Isolation of a specific (µ-opiate receptor peptide, morphiceptin, from an enzymatic digest of milk proteins. J. Biol. Chem. (1985) 260(17):9706-9712.
   PubMed Web of Science ®Google Scholar
• SALERNO C, CRIFO C: Urinary methylxanthine and autistic disorder: Absence of previously reported correlation. Nucleosides Nucleotides Nucleic Acids (2004) 23(8-9):1249-1251.
   PubMed Web of Science ®Google Scholar
• STURMEY P: Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials. Res. Dev. Disabil. (2005) 26(1):87-97.
   PubMed Web of Science ®Google Scholar
• WILLIAMS K, WRAY J, WHEELER D: Intravenous secretin for autism disorder. Cochrane Database Syst. Rev. (2005) Issue 3.
   Google Scholar
• ESCH BE, CARR JE: Secretin as a treatment for autism: a review of the evidence. J. Autism Dev. Disord. (2004) 34(5):543-556.
   PubMed Web of Science ®Google Scholar
• BAYLISS HP, STARLING EH: Mechanism of pancreatic secretin. J. Physiol. (1902) 28:325-353.
   PubMedGoogle Scholar
• NOZAKI S, NAKATA R, MIZUMA H et al.: In vitro autoradiographic localization of 125I-secretin receptor binding sites in rat brain. Biochem. Biophys. Res. Commun. (2002) 292(1):133-137.
   PubMedGoogle Scholar
• YUNG WH, LEUNG PS, NG SS, ZHANG J, CHAN SC, CHOW BK: Secretin facilitates GABA transmission in the cerebellum. J. Neurosci. (2001) 21(18):7063-7068.
   PubMed Web of Science ®Google Scholar
• KARELSON E, LAASIK J, SILLARD R: Regulation of adenylate cyclase by galanin, neuropeptide Y, secretin and vasoactive intestinal polypeptide in rat frontal cortex, hippocampus and hypothalamus. Neuropeptides (1995) 28(1):21-218.
   PubMedGoogle Scholar
• SAMSON WK, LUMPKIN MD, MCCANN SM: Presence and possible site of action of secretin in the rat pituitary and hypothalamus. Life Sci. (1984) 34(2):155-163.
   PubMedGoogle Scholar
• GOULET M, SHIROMANI PJ, WARE CM, STRONG RA, BOISMENU R, RUSCHE JR: A secretin i.v. infusion activates gene expression in the central amygdale of rats. Neuroscience (2003) 118(4):881-888.
   PubMedGoogle Scholar
• CHARLTON CG, MILLER RL, CRAWLEY JN, HANDELMANN GE, O’DONOHUE TL: Secretin modulation of behavioral and physiological functions in the rat. Peptides (1983) 4(5):739-742.
   PubMedGoogle Scholar
• NG SS, YUNG WH, CHOW BK: Secretin as a neuropeptide. Mol. Neurobiol. (2002) 26(1):97-107.
   PubMedGoogle Scholar
• LIM MM, BIELSKY IF, YOUNG LJ: Neuropeptides and the social brain: potential rodent models of autism. Int. J. Dev. Neurosci. (2005) 23(2-3):235-243.
   PubMed Web of Science ®Google Scholar
• MODAHL C, GREEN L, FEIN D et al.: Plasma oxytocin levels in autistic children. Biol. Psychiatry (1998) 43(4):270-277.
   PubMed Web of Science ®Google Scholar
• GREEN L, FEIN D, MODAHL C, FEINSTEIN C, WATERHOUSE L, MORRIS M: Oxytocin and autistic disorder: alterations in peptide forms. Biol. Psychiatry (2001) 50(8):609-613.
   PubMed Web of Science ®Google Scholar
• KIM SJ, YOUNG SJ, GONEN D et al.: Transmission disequilibrium testing or arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol. Psychiatry (2002) 7(5):503-507.
   PubMed Web of Science ®Google Scholar
• WU S, JIA M, RUAN Y et al.: Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han Population. Biol. Psychiatry (2005) 58(1):74-77.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, NOVOTNY S, HANRATTY M et al.: Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology (2003) 28(1):193-198.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN R, JOJA O, PSATTA DM, PETRESCU M, PARASCHIV I, POPA M: Vasotocin improves intelligence and attention in mentally retarded children. Physiol. Behav. (1989) 46(6):967-970.
   PubMedGoogle Scholar
• GRAVES CR: Agents that cause contraction or relaxation of the uterus. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Chapter 39 (9th Edition). McGraw-Hill Companies, New York, USA (1996).
   Google Scholar
• HUNTER DJ, SCHULZ P, WASSENAAR W: Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin. Pharmacol Ther. (1992) 52(1):60-67.
   PubMed Web of Science ®Google Scholar
• JYONOUCHI GL, RUBY A, REDDY C, ZIMMERMAN-BIER B: Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J. Pediatr. (2005) 146(5):605-610.
   PubMedGoogle Scholar
• JYONOUCHI H, SUN S, LE H: Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J. Neuroimmunol. (2001) 120(1-2):170-179.
   PubMed Web of Science ®Google Scholar
• BOLTE ER: Autism and Clostridium tetani. Med. Hypotheses (1998) 51(2):133-134.
   PubMed Web of Science ®Google Scholar
• SANDLER RH, FINEGOLD SM, BOLTE ER et al.: Short-term benefit from oral vancomycin treatment of regressive-onset autism. J. Child Neurol. (2000) 15(7):429-435.
   PubMed Web of Science ®Google Scholar
• FATEMI SH, HALT AR, STARY JM, KANODIA R, SCHULZ SC, REALMUTO GR: Glutamic acid decarboxylase 65 & 67 kDa proteins are reduced in autistic parietal & cerebellar cortices. Biol. Psychiatry (2002) 52(8):805-810.
   PubMed Web of Science ®Google Scholar
• DARMAUN D, WELCH S, RINI A, SAGER BK, ALTOMARE A, HAYMOND MW: Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am. J. Physiol. (1998) 274(5, Pt.1):801-807
   Google Scholar
• BRUSILOW SW: Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res. (1991) 29(2):147-150.
   PubMed Web of Science ®Google Scholar
• LAKE CR, ZIEGLER MG, MURPHY DL: Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch. Gen. Psychiatry (1977) 34(5):553-556.
   PubMed Web of Science ®Google Scholar
• MINDERAA RB, ANDERSON GM, VOLKMAR FR, AKKERHUIS GW COHEN DJ: Noradrenergic and adrenergic functioning in autism. Biol. Psychiatry (1994) 36:237-241.
   PubMed Web of Science ®Google Scholar
• CROONENBERGHS J, DELMEIRE L, VERKERK R et al.: Peripheral markers of serotonergic and noradrenergic function in post-pubertal, Caucasian males with autistic disorder. Neuropsychopharmacology (2000) 22(3):275-283.
   PubMed Web of Science ®Google Scholar
• ROBINSON PD, SCHUTZ CK, MACCIARDI F, WHITE BN, HOLDEN JJ: Genetically determined low maternal serum dopamine β-hydroxylase levels and the etiology of autism spectrum disorders. Am. J. Genet. (2001) 100(1):30-36.
   Google Scholar
• POSEY DJ, GUENIN KD, KOHN AE, SWIEZY NB, MCDOUGLE CJ: A naturalistic open-label study of mirtazapine in autistic and other pervasive development disorders. J. Child Adolesc. Pyschopharmacol. (2001) 11(3):267-277.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, KAPLAN A, CARTWRIGHT C, REICHMAN D: Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J. Child Neurol. (2000) 15(2):132-135.
   PubMed Web of Science ®Google Scholar
• TUCHMAN R, RAPIN I: Epilepsy in autism. Lancet Neurol. (2002) 1(6):352-358.
   PubMed Web of Science ®Google Scholar
• TREVATHAN E: Seizures and epilepsy among children with language regression and autistic spectrum disorder. J. Child Neurol. (2004) 19(Suppl.1):S49-S57.
   Google Scholar
• ASANO E, CHUGANI DC, MUZIK O: Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology (2001) 57(7):1269-1277.
   PubMed Web of Science ®Google Scholar
• DELONG GR, HEINZ ER: The clinical syndrome of early-life bilateral hippocampal sclerosis. Ann. Neurol. (1997) 42(1):11-17.
   PubMedGoogle Scholar
• HOLLANDER E, DOLGOFF-KASPAR R, CARTWRIGHT C, RAWITT R, NOVOTNY S: An open-trial of divalproex sodium in autism spectrum disorders. J. Clin. Psychiatry (2001) 62(7):530-534.
   PubMed Web of Science ®Google Scholar
• UVEBRANT P, BAUZIENE R: Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics (1994) 25(6):284-289.
   PubMed Web of Science ®Google Scholar
• BELSITO KM, LAW PA, KIRK KS, LANDA RJ, ZIMMERMAN AW: Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo controlled trial. J. Autism Dev. Disord. (2001) 31(2):175-181.
   PubMed Web of Science ®Google Scholar
• HARDAN AY, JOU RA, HANDEN BL: A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. J. Child Adolescent Psychopharm. (2004) 14(3):426-432.
   PubMed Web of Science ®Google Scholar
• HOSHINO Y, KUMASHIRO H, YAMAMOTO T et al.: Plasma cyclic AMP levels in psychiatric diseases of childhood. Folia Psychiatr. Neurol. Jpn. (1980) 34(1):9-16.
   PubMedGoogle Scholar
• GOLDBERG M, HATTAB J, MEIR D, EBSTEIN RP, BELMAKER RH: Plasma cyclic AMP and cyclic GMP in childhood-onset psychoses. J. Autism Dev. Disorders (1984) 14(2):159-164.
   PubMedGoogle Scholar
• PAGE T, COLEMAN M: Purine metabolism abnormalities in a hyperuricosic subclass of autism. Biochim. Biophys. Acta (2000) 1500(3):291-296.
   PubMed Web of Science ®Google Scholar
• PAGE T, MOSELEY C: Metabolic treatment of hyperuricosuric autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. (2002) 26(2):397-400.
   PubMedGoogle Scholar
• ANDRIEUX A, SALIN PA, VERNET M et al.: The suppression of cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev. (2002) 16(18):2350-2364.
   PubMed Web of Science ®Google Scholar
• FRADLEY RL, O’MEARA GF, NEWMAN RJ, NDRIEUX A, JOB D, REYNOLDS DS: STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. (2005) 163(2):257-264.
   PubMedGoogle Scholar
• BRUN P, BEGOU M, ANDRIEUX A et al.: Dopaminergic transmission in STOP null mice. J. Neurochem. (2005) 94(1):63-73.
   PubMedGoogle Scholar
• ASHWOOD P, VAN DE WATER J: Is autism an autoimmune disease? Autoimmun. Rev. (2004) 3(7-8):557-562.
   PubMedGoogle Scholar